Yes, immediate-release diltiazem and verapamil cause bradycardia
Both immediate-release diltiazem and verapamil are well-documented to cause bradycardia as a direct consequence of their pharmacologic effects on cardiac conduction. These nondihydropyridine calcium channel blockers have prominent effects on the sinoatrial (SA) and atrioventricular (AV) nodes, resulting in negative chronotropic effects that slow heart rate 1, 2.
Mechanism and Clinical Evidence
Diltiazem and verapamil work by blocking L-type calcium channels in cardiac tissue, particularly affecting nodal tissue. This mechanism:
- Prolongs the effective refractory period within the AV node
- Slows AV conduction in a rate-related manner
- Can interfere with sinus-node impulse generation 3
Multiple authoritative guidelines explicitly list bradycardia as a side effect for both drugs 1, 4. The 2013 ACC/AHA guidelines specifically document bradycardia as a known adverse effect in their comprehensive tables of calcium channel blocker properties 1.
Clinical Significance
The bradycardia risk is clinically meaningful:
- Verapamil causes bradycardia frequently enough that it's listed prominently alongside hypotension, myocardial depression, heart failure, and edema as major side effects 1, 4
- Diltiazem similarly lists bradycardia as a key adverse effect, along with hypotension, dizziness, flushing, and edema 1, 4
The 2023 AHA poisoning guidelines note that in overdose situations, nondihydropyridines like diltiazem and verapamil present with "severe shock from bradycardia" among other effects 2. The FDA drug label for verapamil explicitly warns that "bradycardia (rate less than 50 beats/min)" can occur, though it notes this is "uncommon (1.4%)" at therapeutic doses 3.
High-Risk Scenarios
Bradycardia risk increases substantially in certain situations:
Combination with beta-blockers: The 2022 hypertension consensus document warns that combining nondihydropyridine CCBs with beta-blockers carries "a risk of bradycardia and AV block with non-dihydropyridine CCBs, particularly with verapamil, but also with diltiazem at higher doses" 5. Research confirms this, with one study reporting that seven of nine patients hospitalized for severe bradycardia were on combination therapy 6
Renal dysfunction: Patients with chronic kidney disease face increased risk due to drug accumulation 5, 7
Presence of hyperkalaemia: Even mild hyperkalaemia synergistically increases vulnerability to AV conduction delays and bradyarrhythmias 7
Pre-existing conduction abnormalities: Patients with sick sinus syndrome, first-degree AV block, or other conduction disturbances are at heightened risk 3
Practical Considerations
The 2010 AHA ACLS guidelines note that when using these agents for arrhythmia management, "side effects of β-blockers can include bradycardias, AV conduction delays, and hypotension" and similar cautions apply to calcium channel blockers 8. The 2016 SVT guidelines list AV block greater than first degree or SA node dysfunction as contraindications for both drugs 9.
Research data supports clinical vigilance: A 1985 study found that higher doses of verapamil or diltiazem were "not well tolerated, and in eight patients...had to be initiated early due to symptomatic bradycardia" 10. Another study documented "profound hypotension and bradycardia requiring therapy" with verapamil use 11.
The immediate-release formulations carry the same bradycardia risk as sustained-release versions, though the FDA label notes that with immediate-release formulations, bradycardia typically occurs during the early titration phase when plasma concentrations are rising 3.